Palex comenzó su fase de crecimiento acelerado en 2016 con la entrada de Corpfin Capital. A finales de  2021 Fremman tomó la mayoría continuando Corpfin Capital, Ergon y el equipo directivo de Palex como socios minoritarios.

With the incorporation of Wacress, Palex continues to lead the sector and reinforces its organic and inorganic growth plan through acquisitions of complementary companies. Palex will continue to focus on diversification in its product portfolio, innovation and minimally invasive treatments.